Form 4 for SRPT Sarepta Therapeutics, Inc.
Accepted 2025-03-11 00:00:00 ET · period of report 2025-03-07 · accession 0000950170-25-037523 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2025-03-11 | 2025-03-10 | SRPT | Rodino-Klapac Louise | CSO, Head of R, D | F - Tax | $100.13 | -3,463 | 76.4K | -4% | -$346.8K |
| D | 2025-03-11 | 2025-03-10 | SRPT | Rodino-Klapac Louise | CSO, Head of R, D | A - Grant | — | +8,276 | 84.6K | +11% | — |
| D | 2025-03-11 | 2025-03-07 | SRPT | Rodino-Klapac Louise | CSO, Head of R, D | M - OptEx | — | +5,500 | 79.8K | +7% | — |
| D | 2025-03-11 | 2025-03-10 | SRPT | Rodino-Klapac Louise | CSO, Head of R, D | A - Grant | $0.00 | +16.6K | 16.6K | New | $0 |
| D | 2025-03-11 | 2025-03-07 | SRPT | Rodino-Klapac Louise | CSO, Head of R, D | M - OptEx | $0.00 | -5,500 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-03-10 | F | D | 924 | $100.13 | 78,894 | D | — | — | (F2) Shares were sold by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on March 7, 2022. |
| 2 | Common | Common Stock | 2025-03-10 | A | A | 8,276 | — | 84,631 | D | — | — | (F4) The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. 25% of the shares of common stock underlying each RSU will vest on the first anniversary of the grant date, and additional 25% will vest on each anniversary of the Grant Date thereafter, such that the RSUs will be fully vested on the fourth anniversary of the grant date. |
| 3 | Common | Common Stock | 2025-03-10 | F | D | 2,539 | $100.13 | 76,355 | D | — | — | (F3) Shares were sold by the Company to satisfy tax withholding obligations related to vesting of PSUs granted on March 7, 2022. |
| 4 | Common | Common Stock | 2025-03-07 | M | A | 5,500 | — | 79,818 | D | — | — | (F1) Represents the number of shares vested under a performance stock unit ("PSU") award granted to the Reporting Person on March 7, 2022. The number of shares earned was based on the Compensation Committee's determination of the Company's achievement of the milestones under the terms of the PSU. |
| 5 | Derivative | Stock Options (right to buy) | 2025-03-10 | A | A | 16,644 | $0.00 | 16,644 | D | $99.69 · 2026-03-10 to 2035-03-10 | 16,644 Common Stock | (F5) Represents the date upon which the first 25% of the option granted vests. 1/48th of the total granted option vests and become exercisable on each monthly anniversary thereafter. |
| 6 | Derivative | Performance Stock Units | 2025-03-07 | M | D | 5,500 | $0.00 | 0 | D | — · — to — | 5,500 Common Stock | (F1) Represents the number of shares vested under a performance stock unit ("PSU") award granted to the Reporting Person on March 7, 2022. The number of shares earned was based on the Compensation Committee's determination of the Company's achievement of the milestones under the terms of the PSU. |